Is Zurzuvae approved by the FDA for treating postpartum depression in adults?

Zurzuvae (zuranolone) is a medication specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of postpartum depression (PPD) in adults. It is a neuroactive steroid that works by modulating GABA receptors in the brain. The approval was announced on August 4, 2023, making it the first oral medication approved for PPD, offering a convenient outpatient treatment option.

What the research says

The FDA approval of Zurzuvae for postpartum depression is well-documented in multiple sources. Source ⁵ directly states the indication: 'ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults.' This is corroborated by peer-reviewed literature. Source ¹⁰ notes that 'Zuranolone (Zurzuvae) was approved by the US FDA on 4 August 2023 for the management of PPD.' Source ¹¹ confirms that 'Zuranolone is only the second medication approved by the Food and Drug Administration (FDA) for PPD' and highlights its advantage as an oral medication that can be taken at home. Additionally, source ⁹ describes zuranolone as 'the first US Food and Drug Administration-approved drugs for postpartum depression' (along with brexanolone), emphasizing its significance in addressing unmet needs. Clinical trials showed statistically significant improvement in depressive symptoms at day 15 and sustained remission at day 45 compared to placebo, with common side effects including somnolence, dizziness, headache, and sedation ¹¹.

What to ask your doctor

• Is Zurzuvae (zuranolone) a suitable treatment option for my postpartum depression?
• What are the potential side effects of Zurzuvae, and how can they be managed?
• How does Zurzuvae compare to other treatments like brexanolone or traditional antidepressants?
• What is the recommended dosing schedule for Zurzuvae, and how long is the treatment course?
• Are there any specific precautions or contraindications I should be aware of before starting Zurzuvae?